Sobi takes stake in Selecta gout program

12 June 2020
sobi-logo-big

A strategic licensing agreement has been reached between Stockholm’s Swedish Orphan Biovitrum (STO: SOBI), also dubbed Sobi, and Massachusetts-based Selecta Biosciences (Nasdaq: SELB).

The firms are partnering around the late-stage asset SEL-212, a gout candidate for which Phase III tests are due to commence later this year.

In recent years, Sobi has been investing to develop a stronger position in immunology, coupled with a substantial US base for expansion and growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology